News Channels

30 Jul 2021 FDA Approves Expanded BOTOX® (onabotulinumtoxinA) Label to Include Eight New Muscles to Treat Adults with Upper Limb Spasticity
30 Jul 2021 FDA broadens existing emergency use of Lilly and Incyte's baricitinib in patients hospitalized with COVID-19 requiring oxygen
30 Jul 2021 Lilly releases donanemab data that demonstrated relationship between reduction of amyloid plaque and slowing of cognitive decline
29 Jul 2021 Lilly and Kumquat Biosciences Announce Collaboration to Discover and Develop Novel Small Molecules that Stimulate Tumor-Specific Immune Responses
29 Jul 2021 Dupixent® (dupilumab) Significantly Improved Itch and Hives in Patients with Chronic Spontaneous Urticaria, a Step Forward in Demonstrating the Role of Type 2 Inflammation in These Patients
29 Jul 2021 FDA Accepts Application for Genentech’s Faricimab for the Treatment of Wet Age-Related Macular Degeneration (AMD) and Diabetic Macular Edema (DME)
29 Jul 2021 Fusion Pharmaceuticals Announces FDA Clearance of IND for FPI-1966, an Investigational Radiopharmaceutical for the Treatment of Head and Neck and Bladder Cancers Expressing FGFR3
29 Jul 2021 Viatris Inc. and Biocon Biologics Receive Historic Approval for First Interchangeable Biosimilar Semglee® (insulin glargine-yfgn injection) for the Treatment of Diabetes
28 Jul 2021 Reneo Pharmaceuticals Announces First Patient Dosed in the STRIDE Study
28 Jul 2021 Disc Medicine Initiates Phase 1 Clinical Study of DISC-0974, a First-In-Class Inhibitor of Hemojuvelin (HJV) in Development for the Treatment of Anemia of Inflammation
28 Jul 2021 Zucara Therapeutics Doses First Patients in Phase 1b Trial of ZT-01
28 Jul 2021 Bridge Medicines Enters Exclusive License Agreement with Cornell University for UBR5 Inhibitor Program to Treat Resistant Cancers
28 Jul 2021 ENYO Pharma Announces Positive Vonafexor (EYP001) Results for the LIVIFY Phase 2a Study in F2-F3 NASH Patients over 12 weeks
28 Jul 2021 Venatorx Pharmaceuticals Announces Positive Phase 1 Results for VNRX-7145
28 Jul 2021 M6P Therapeutics Presented Data on M041, A Recombinant Enzyme Therapy, for the Treatment of Sanfilippo B Syndrome at MPS 2021
28 Jul 2021 NewAmsterdam Pharma Reports Positive Results from Phase 2 Study of Oral Obicetrapib Demonstrating Over 50% LDL-Lowering as an Adjunct to High-Intensity Statins
28 Jul 2021 Zymeworks Announces First Patient with Advanced HER2-Positive Breast Cancer Dosed with Zanidatamab in Combination with Tukysa® (Tucatinib) and Chemotherapy
28 Jul 2021 Arcturus Announces Regulatory Approval to Proceed with Phase 2 Study of ARCT-810 mRNA Therapeutic Candidate for Ornithine Transcarbamylase (OTC) Deficiency
28 Jul 2021 U.S. Food and Drug Administration Grants Breakthrough Therapy Designation to Takeda’s Investigational Compound, TAK-994, an Oral Orexin Agonist in Clinical Development for Narcolepsy Type 1 (NT1)
28 Jul 2021 PeptiDream and Takeda Expand Collaborative Research and License Agreement to Develop Peptide Drug Conjugates for CNS Diseases

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2020 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up